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Riassunto 
Il melanoma  rappresenta la forma più aggressiva di cancro della pelle 
 e si origina per trasformazione neoplastica dei melanociti. L’esposizione ai 
raggi UV e la suscettibilità genetica rappresentano i  principali fattori di 
rischio per lo sviluppo di questa patologia, che  risulta particolarmente 
resistente a diversi tipi di trattamenti terapeutici e chemioterapici. In 
quest’ottica, negli ultimi anni, sono stati identificati nuovi pathways di 
segnalazione cellulare, coinvolti nella tumorigenesi, al fine di individuare 
nuovi bersagli per le  terapie.                                                                                
 Nella progressione del melanoma è noto che il fattore di trascrizione 
nucleare NF-kB risulta costitutivamente attivato in diverse linee di 
melanoma  ed in grado di regolare l'espressione e la funzione di un ampio 
spettro di geni coinvolti nella risposta immediata ad agenti patogeni, 
nell’infiammazione, nella proliferazione e sopravvivenza cellulare e  
nell'apoptosi.  
Alla luce di queste conoscenze, pertanto, si è ipotizzato che  la sua  
inattivazione potesse indurre le cellule trasformate verso morte 
programmata. A tale scopo,  cellule di melanoma umano A375 sono state 
incubate per tempi diversi  con differenti concentrazioni di NBD-peptide, un 
peptide di cui erano già note le proprietà antinfiammatorie.                                                                                                                                            
Nell’ambito di questo studio la poli(ADPR)polimerasi1 (PARP-1) è stata 
scelta come marcatore di apoptosi. E’ noto, infatti, che la PARP-1  
(113kDa) è substrato della caspasi 3, che opera la sua  proteolisi  in due 
frammenti stabili ed inattivi (89kDa e 24kDa). I risultati ottenuti hanno 
evidenziato che il trattamento con NBD-peptide induce una inibizione della 
proliferazione cellulare dipendente dalle concentrazioni di peptide utilizzate. 
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La conferma che le cellule trattate muoiono per apoptosi è stata ottenuta sia 
mediante citometria a flusso (FACS analysis) che attraverso le analisi di 
espressione e di attività della PARP-1. L’analisi al FACS ha, infatti, 
mostrato che nelle cellule trattate si verifica attivazione della  caspasi-3, 
responsabile della parziale frammentazione ed inattivazione della PARP-1 
osservate rispettivamente mediante Western blotting e misura di attività 
enzimatica.   
Il saggio EMSA (electrophoretic mobility shift assay) effettuato per 
determinare l’attività sia di NF-kB, che  del complesso IkB chinasi (IKK), 
hanno confermato l’ipotesi che il peptide induce apoptosi attraverso la 
modulazione  del fattore di trascrizione nucleare. Tale modulazione è 
conseguenza del blocco dell’attività del complesso IKK,  responsabile 
dell’attivazione dil NF-kB. E’ noto, infatti, che quest’ultimo, in forma non 
attivata, non può traslocare nel nucleo, dove è responsabile della trascrizione 
di diversi tipi di geni, tra i quali quelli antiapoptotici.  
I dati preliminari suggeriscono anche che la parziale  inattivazione della 
PARP-1 potrebbe contribuire al mantenimento del processo apoptotico.   
  Poiché  è stato dimostrato che anche i livelli di poli-ADP-ribosio (PAR) 
giocano un ruolo cruciale sia nella vita che nella morte cellulare,  nella 
seconda fase di ricerca  sono stati condotti studi atti a  verificare se nelle 
cellule di melanoma il trattamento con NBD-peptide modifica il turnover 
del poli-ADP-ribosio. A tale scopo è stata studiata, oltre alla sintesi del poli-
ADP-ribosio, anche la sua degradazione, della quale è responsabile la 
poli(ADPR)glicoidrolasi (PARG). 
Nelle cellule di melanoma A375  trattate e non con NBD peptide, è espressa  
la stessa isoforma dell’ enzima PARG con un peso molecolare di circa 
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75kDa, a localizzazione nucleare. L’attività dell’enzima è 
significativamente più elevata nelle cellule di melanoma non trattate, nelle 
quali è garantito un attivo “turnover” di PAR ed è favorita la sopravvivenza 
della cellula tumorale. 
Nelle cellule trattate, i più bassi livelli di attività della PARG potrebbero 
essere spiegati considerando che la sua attività è influenzata sia dalla 
lunghezza del PAR che dalla sua concentrazione intranucleare. La parziale 
inattivazione della PARP-1 indica, infatti, che i livelli di PAR nelle cellule 
trattate sono più bassi di quelli prodotti nelle cellule di melanoma. Inoltre, in 
seguito ad isolamento del PAR, è stato osservato che  il polimero 
proveniente dalle cellule A375 di melanoma trattate è più corto e non 
ramificato di quello delle cellule non trattate. 
  In conclusione possiamo ipotizzare che nelle cellule trattate, dove il 
processo apoptotico è attivo, i bassi livelli di attività PARP-1 producono  
livelli di PAR  bassi e non tossici, i quali combinati con una bassa attività 
dell’enzima PARG potrebbero consentire alla cellula di mantenere lo stato 
apoptotico piuttosto che andare in necrosi.   
Nell’ultima fase della ricerca  è stata confermata l’efficacia del peptide 
NBD  anche su altre sei linee di melanoma con diverse mutazioni geniche. 
 L’ impiego del peptide NBD, pertanto potrebbe rappresentare un innovativo 
ed efficiente strumento per la cura del melanoma. A differenza dei comuni 
farmaci  utilizzati per l’inibizione dell’attività di NF-kB, inoltre,   NBD-
peptide non determina la totale inattivazione del fattore trascrizionale, 
consentendone un ruolo fisiologico nell’immunità, nell’infiammazione e 
nell’omeostasi cellulare.  
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Summary 
Melanoma is the most aggressive form of skin cancer that originates  
from neoplastic trasformation of melanocyte cells. Important predisposing 
factors are considered UV exposure and genetic susceptibility. Due to the 
complex nature of the disease, metastatic melanomas have proven to be 
typically resistant to different therapy and chemotherapy treatments. On  
this basis, recently, key signalling pathways that are important in promoting 
melanoma tumourigenesis, have been identified thus providing dynamic 
targets for therapy.  
The NF-kB is a well known transcriptional nuclear factor involved in 
melanoma progression. It is constitutively activated in several melanoma 
cell lines and  regulates  the expression and function  of several genes 
involved in immediate early pathogen response, in inflammation, cell 
proliferation and survival and in apoptosis. 
Based on this knowledge, it was hypothesized that its inhibition could 
represent a new way to induce programmed death in tumoral cells. 
Therefore, A375 melanoma cells were incubated with different 
concentrations of NBD-peptide at different times. The anti-inflammatory  
activity of this peptide was already known. 
 In this study, PARP-1 was used as marker of apoptotic process. In fact, it is 
a substrate of caspase-3, responsible for its cleavage in two stable and 
inactive fragments (89kDa and 24kDa). The results showed that the NBD 
peptide treatment induces a concentration-dependent inhibition of 
melanoma cell proliferation.  
FACS analysis (flow cytometry) using the monoclonal antibody (mAb) PE-
conjugated anti-human-active caspase-3, together with  PARP-1 expression 
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and activity analyses, confirmed that the treated cells die by apoptosis. 
FACS analysis showed that in treated cells, a concentration-dependent 
activation of caspase-3 occurs. Partial fragmentation and inactivation of 
PARP-1, is also observed by western blotting and enzimatic assay, 
respectively.  
EMSA assay (electrophoretic mobility shift assay) carried out to study both 
NF-kB and IKK kinase complex activities, confirmed the hypothesis that the 
peptide induces apoptosis by modulating activity of this transcriptional 
nuclear factor. Such modulation is due to the block of IKK complex 
activity, responsible of NF-kB activation. In fact,  it’ s known  that  the 
latter, inactive, cannot translocate into nucleus, where it modulates  
transcription of different genes among which the  antiapoptotic genes.  
Preliminary data also suggest that partial PARP-1 inactivation could allow 
the maintenance of apoptotic process. PARP-1, in fact, is one of the main 
consumers of intracellular energy.  
Since it was demonstrated that poly-ADP-ribose (PAR) levels play an 
important role both in cellular survival and death, in the second part of the 
present research it was studied whether NBD peptide treatment influences 
poly-ADP-ribose turnover. To this aim, beside poly-ADP-ribose synthesis,  
its degradation, by poly(ADPR)glycohydrolase (PARG) was studied. 
In both NBD  treated and untreated A375 melanoma cells,  the same PARG 
isoform is expressed (about 75kDa), localized into the nucleus.  
Its activity is more high in untreated melanoma cells, in which an active 
PAR turnover is guaranteed and tumoral  cell survival occurs. 
In treated cells, the lowest activity of PARG could depend on both length 
and intranuclear concentration of PAR. The partial PARP-1 inactivation 
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suggests that PAR levels in treated cells are lower than those produced in 
melanoma cells. Moreover, a comparison of  PAR isolated from treated cells 
and that from melanoma cells, indicates  that the former is unbranched and 
shorter.  
In conclusion, it is possible to hypothesize that in treated A375 cells, where 
the apoptotic process occurs, the low PARP activity produces low and no 
toxic PAR levels that combined with a low PARG activity, might allow the 
cells to maintain the apoptotic state rather than undergo necrosis. 
In the last part of research the efficience of NBD peptide was also tested on 
other seven melanoma cell lines with different gene mutations. So, this 
peptide might represent a new and efficient drug in melanoma care. In 
addition, respect to common drugs used to inhibit NF-kB activity, NBD-
peptide doesn’t block nuclear factor activity completely, allowing its 
physiological roles in immunity, inflammation and cellular homeostasis. 
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INTRODUCTION  
 
1.1 Poly(ADP-ribosyl)ation reaction and PARP enzymes  
 
Poly(ADP-ribosyl)ation is a post-translational modification of proteins 
involved in a wide range of molecular and cellular processes, including 
DNA damage detection and repair, chromatin modification, apoptosis, 
proliferation, differentiation and mitotic apparatus function (Hottiger et    
al., 2010). 
These processes are critical for many physiological and pathophysiological 
outcomes (genome maintenance, carcinogenesis, aging, inflammation, and 
neuronal function) (Mègnin. et al., 2010., Rupinder et al., 2010., 
Strosznajder et al., 2010). 
The reaction  is mediated by  mono- and poly(ADP-ribosyl) transferases  
(PARPs), enzymes that use NAD
+
 as  substrate to transfer  successive ADP-
ribose units to glutamic or aspartic acid residues of target proteins, giving 
rise  to long and branched ADP-ribose polymers (Amè et al., 2004). 
The synthesis of poly-ADP-ribose requires three distinct steps: 
 hydrolysis of N-glycosidic bond between nicotinamide and ribose, 
with release of molecules of adenosine diphosphate ribose (ADPR), 
and concomitant formation of an ester bond between ADPR and the 
first unit of a specific amino acid of the acceptor protein. 
 Elongation whereby further ADP-ribose moieties are attached to 
protein bound ADP-ribosyl residues.  
 Introduction of an ADP-ribose residue which branches off from a 
linear portion of the polymer. 
Introduction 
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All the members belonging to the PARP family have different size, cellular 
localization and role (Nguewa et al., 2005). 
The most know PARP-1 and PARP-2, PARP-3, tankirase1, v-PARP are 
localized in different subcellular sites, respectively nucleus, centrosome, 
telomers and vaults particle in cytoplasm (Hassa et al., 2008). Some of the 
recently discovered PARPs (PARP-6, PARP-16 and PARP-10) seem to be 
closer to ADP-rybosyltransferases, as they catalyze mono-ADP-
ribosylation, (Kleine et al., 2008). 
 
 
 
Figure 1: Chemical structures of Nicotinamide Adenine Dinucleotide (NAD
+
) 
and poly-ADP-ribose (PAR). The synthesis of long and branched PAR, catalyzed by 
PARPs is described. 
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Hottiger et al., (2010), proposed a new nomenclature based on sequence and  
structure homology search of the conservative ADP-ribosyltransferase fold 
and enlarged the family of ADP-ribosylating enzymes by including mono- 
and poly- ADP-ribosylation proteins, and named all members as ARTs. 
       
 
                 
Figure 2: A new  schematic comparison of the functional domains of the human 
ARTD (PARP) family. 
The most  relevant are: ART, is the catalytic core required for basal ART activity. PARP 
regulatory domain (PRD) might be involved in regulation of the PARP-branching activity. 
WGR, characterized by the conserved central motif (W-G-R), is also found in a variety of a 
polyA polymerase and in proteins of unknow function. BRCT domain (BRCA 1 carboxy-
terminaldomain) is found within many DNA damage repair and cell cycle checkpoint 
protein.  Macro domain can serve as ADPR or 0-acetyl-ADPribose binding module. ZF: 
zinc finger domains, recognizing DNA breaks (Hottiger et al., 2010).  
Introduction 
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Poly(ADP-ribose) polymerase-1 (PARP-1), also known as poly (ADP-
ribose) transferase and poly(ADP-ribose) synthetase is the most extensively 
studied and the founding member of the PARP family. It is a nuclear  
protein (113kDa) having highly conserved structural and functional 
organization including an N-terminal double zinc finger DNA-binding 
domain (DBD), a nuclear localization signal, a central automodification 
domain (PARP-1 itself  is an acceptor of  poly-ADPR), and a C-terminal 
catalytic domain as shown in Figure 3 (Eustermann et al., 2011; Tao et al., 
2009., Virág, et al., 2005). 
 
 
Figure 3: Schematic molecular structure of human PARP-1 enzyme domains 
(Mègnin-Chanet et al., 2010). 
 
DBD of PARP-1 binds to single or double strand breaks with high affinity 
through its two zinc fingers. 
The first zinc finger is essential for PARP-1 activation by DNA double 
strand breaks, whereas the second zinc finger is important for PARP-1 
activation by single strand breaks but not the double strand breaks. When 
DNA is moderately damaged, PARP-1 participates in DNA repair process 
and cell survival. 
However, in case of extensive DNA damage, PARP-1 over activation 
induces a decrease in NAD
+
 and consequently in ATP levels, leading to cell 
dysfunction and death  (Gagne et al., 2006; Meyer-Ficca et al., 2005). 
Therefore over activation of PARP was implicated in the pathogenesis of 
Introduction 
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several diseases including stroke (Kauppinen et al., 2007), myocardial 
infarction (Szabo et al., 2005), neurodegenerative disorders  (Koh et al., 
2005), diabetes (De la Lastra et al., 2007) and several other inflammatory 
disorders several type of tumors and cellular death  (Hamby et al., 2007).  
To this regard, PARP-1 is considered as an effective biological marker  in 
many types of  human tumours, including melanoma (Mègnin-Chanet et al., 
2010., Zaremba et al., 2009). It’s known that many tumors are resistant to 
classic anti-tumoral drugs which most probably inhibit the apoptotic 
pathways.  In fact,  in tumor cells anti-tumor drugs can induce only necrosis, 
being ATP levels very low to support the apoptotic process.  
In this optic,  the role of PARP as a molecular switch between necrosis and 
apoptosis led to investigate about the use of inhibitors of PARP-1, to reduce 
high consumption of ATP and thereafter to induce apoptosis in tumoral 
cells. (Fauzee et al., 2010.,  Chol Ha et al., 1999). 
 
 
 
Figure 4: Intensity of DNA damage determines the fate of cell. In case of low levels of 
DNA damage poly(ADP)ribosilation causes DNA repair and cellular recovery. Moderate 
levels of DNA damage activates apoptotic pathway. Severe DNA damage induces 
iperactivation of PARP depleting NAD
+
/ATP stores resulting in necrosis (Rupinder et al., 
2010). 
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PARP-1 inhibitors increase antitumoral drugs activity representing a 
potential new strategy to control haematological and solid malignancies 
(Comen et al., 2010.,  Peralta et al., 2009). 
In addition, PARP-1 is the best marker of apoptosis, as in the last phase of 
this process, caspase 3 and 7 recognize the motif in the nuclear localization 
signal of PARP-1 and cleave it into two fragments, ~p89 and ~p24; the 
cleavage at this site separates the DNA binding domain from the  catalytic 
domain rendering PARP inactive. 
Recent studies show that PARP-1 plays a role in caspase independent 
apoptotic cell death by AIF (apoptosis inducing factor); PARP-1 activation 
induces the translocation of AIF from mitochondria to nucleus, where it 
causes DNA fragmentation and apoptotic cell death (Koh et al., 2005). 
Beside its catalytic function, PARP-1 is also  partner of other proteins to 
form complex regulating different nuclear functions and contributing to the 
maintenance of genomic stability. It has been widely demonstrated the role 
of PARP-1 as coactivator of Nuclear factor-kB. The automodification of 
PARP-1 positively up-regulates formation of the NF-kB-DNA complex and 
enhances transcriptional activation. However, unmodified PARP-1 reduces 
the DNA binding of NF-kB via its physical association with NF-kB (Chang 
et al., 2001., Hassa et al., 2006). 
Several  studies led to the discovery of a second DNA-damage-activated 
PARP, PARP-2, that is also a nuclear protein and forms PAR in response to 
DNA damage. The activity of PARP-2 accounts for approximately 10% of 
the total PARP activity of human cells (Amè et al., 1999). Among the 
PARP family members, PARP-2 is the closest relative of PARP-1 with their 
catalytic F-domains having approximately 69% similarity. The N-terminal 
Introduction 
 7 
domain of murine PARP-2 does not contain zinc-finger motifs but a highly 
basic DBD, a NLS and a nucleolar localization signal which displays 
homology with the SAP domain found in various nuclear proteins like APE-
1 and Ku-70, involved in chromosomal organization or DNA repair. The 
PARP-2 DBD is structurally different from that of PARP-1, probably 
reflecting differences in the DNA structures recognized by each enzyme 
(Amè et al., 2005). The PARP-2 E domain acts both as the interacting 
interface with various partners and as an auto-modification domain. PARP-1 
and PARP-2 can homo-and hetero-dimerize and poly(ADP-ribose)ate each 
other (Schreiber et al., 2004). 
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1.2 Poly(ADP- ribose) catabolism 
The removal of PAR from the modified proteins is catalyzed by an  
 enzyme, the poly(ADP-ribose) glycohydrolase (PARG), which is encoded 
by a single gene (Min, et al., 2009.,  Gagne et al., 2006). PARG possesses 
an exo- and endoglycosidase activity that hydrolyzes ribosyl-ribose bonds 
and produces free ADP-ribose (ADPR) residues from both linear and 
branched poly(ADP-ribose). Thereafter an ADP-ribose lyase is responsible 
for the cleavage between the first ADP-ribose and modified amino acids. 
The concerted action of these enzymes modulates the level and complexity 
of polymer on different acceptor proteins (Bonocalzi et al., 2005), 
preventing an accumulation of highly modified nuclear proteins with very 
long chains of PAR, including PARP-1 itself. The catabolism of poly-
(ADPR) allows PARP-1 to remain active in conditions of DNA damage, 
because it assures interactions between the enzyme and genoma. 
It has been demonstrated that the gene encoding human PARG is 
alternatively spliced to generate three different protein isoforms with 
molecular weights of, 110, 103 and 99 kDa, respectively (Meyer-Ficca et 
al., 2004). Several studies have shown that PARG110 localizes 
predominantly to the nucleus (Ohashi et al., 2003), while PARG103 and 
PARG99 isoforms are cytoplasmic (Bonocalzi et al., 2003). Interestingly, 
the cytoplasmic PARG103 isoform accounts for nearly 90% of the entire 
cellular activity . The PARG enzyme contains a C-terminal catalytic domain 
and a N-terminal putative regulatory domain which would be involved in 
protein–protein interactions (Ame et al., 1999). 
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Importantly, all PARG isoforms, like PARP-1, has been found to be 
efficiently cleaved by caspase-3 in human cells undergoing apoptosis (Affar 
et al., 2001). This cleavage of PARG releases enzymatically active C-
terminal fragments of 85 or 74kDa and these PARG85 and PARG74 
apoptotic fragments are localized in the cytoplasm  too (Bonocalzi et al., 
2003). Apart from these observations, little is known about the biological 
significance of the cellular localization and the presence of different PARG 
isoforms other than they are able to catalyze PAR turnover in different cell 
compartments. The basal levels of polymer within unstimulated cells are 
usually very low (Andrabi et al., 2006) and the nuclear concentration in 
mammalian cells is within the range of one to two times the Km value of 
PARG (Alvarez-Gonzalez, et al., 1989). 
Therefore, the nuclear PAR concentration is sufficient to maintain a 
constant PARG activity, even in unstimulated cells. In response to 
genotoxic stress, the levels of PAR can increase by 10- to 500-fold and this 
event leads to caspase independent cell death (Kang et al., 2004., Yu et al., 
2003) supporting the hypothesis that PAR turnover is essential for cell 
survival.  
Thus, it is extremely important that both cytoplasmic and nuclear levels of 
ADP-ribose polymers are tightly controlled in order to prevent PARP-1 
induced cell death (Koh, et al., 2005.,  Masutani et al., 2003). Therefore, it 
is not surprising that PARG activity has been found to be critical for the 
prevention of PARP-1 dependent cell death by regulating the intracellular 
levels of  PAR (Ying et al., 2001). 
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1.3 Melanoma 
 Melanoma is the  most aggressive  form of  skin   cancer. It originates 
 from neoplastic transformation of melanocyte cells, involved in the 
production of melanin, the  dark pigment that is responsible for giving skin 
its colour. They predominantly occur in skin, but are also found in other 
parts of the body, including the bowel and the eye. Its incidence has 
increased  in the last decade mainly among the  young people.   
 Although causality has been difficult to link with melanoma, sun exposure 
and genetic susceptibility are considered important predisposing factors 
(Amiri et al., 2005). 
The development and progression is viewed in five distinct stages. The 
common acquired nevus is the first step followed by dysplastic nevus 
showing an increased level of structural and architectural atypia.  
.  
                    
 
 
 
Figure 5: Morphological changes in the onset of melanoma.   
 
The third step is the first recognizable malignant stage, defined as the radial 
growth phase (RGP) primary melanoma. The cells in this phase are locally 
invasive but they lack metastatic capacity. Radial growth phase cells can 
progress to vertical growth phase (VGP) primary melanoma lesions, the 
fourth step in progression. 
Asymmetry Irregular edges Colour Size 
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 In this step, melanoma cells infiltrate and invade the dermis as large 
clusters of cells and exhibit metastatic potential. Metastasis to distant organs 
followed by overgrowth of tumor cells at these sites is the final step in the 
progression process (Clark et al., 1991). 
Although this model depicts melanoma progression as a result of series of 
genetic defects intrinsic to melanocytes, our current knowledges about the 
importance of the tumor microenvironment in control of growth, 
differentiation, invasion and metastasis adds to the complexity of the 
disease, hence the challenges faced both in clinics and research laboratories 
in the fight against melanoma. 
 Due to the complex nature of the disease, melanoma has proven to be 
highly resistant to conventional chemotherapy with dacarbazine (DTIC) or 
its derivative Temozolomide (TMZ) having the best single agent activity 
with a response rate of only 15–20% and a short 4 month median response 
duration (Sun et al., 2001). Patients at high risk for recurrence (stage III) are 
frequently given IFN-α as adjuvant treatment, although its effectiveness is 
considered low as compared to toxicity (Punt et al., 2001). Patients with 
metastatic disease (stage IV) have a median survival of 6–10 months with a 
5-year survival of <5% ( Balch et al., 2001). 
 Recent advances to understand the underlying biology in progression of 
melanoma have identified key signaling pathways that are important in 
promoting melanoma tumorigenesis, thus providing dynamic targets for 
therapy. One such important target identified in melanoma tumor 
progression is the nuclear factor-kappa B (NF-κB) pathway (Lin et al., 
2011). 
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1.4 NF-kB and NBD-peptide 
NF-kB is an inducible transcription factor involved in normal immune 
 response which can be activated by different stimuli, including pro-
inflammatory cytokines, “non-self” antigens, lymphocyte mitogens, and 
cellular stress (ultraviolet and ionizing radiations, as well as 
chemotherapeutic agents). 
Constitutive activation of NF-κB is an emerging hallmark of various types 
of tumors and many experimental models in vitro and in animals indicate 
the role of this transcription factor in the regulation of apoptosis, tumor 
angiogenesis and proliferation, as well as tumor cell invasion and 
metastasis. (Karin et al., 2006., Ueda et al., 2006). 
The enhanced activation of NF-kB in tumors appears to be partially due to 
deregulation of upstream kinases such as Ras, Raf, NIK, and AKT that 
impinge on the NF-kB pathway. 
The mammalian NF-kB family contains five proteins, RelA/p65, NF-kB1 
(p50), NF-kB2 (p52), c-Rel and RelB. They exist as homodimers or  
heterodimers  with a wide range of DNA binding and activation potentials. 
In most unstimulated cells NF-kB is sequestered in the citoplasm as an 
inactive transcription factor in a complex with one of  inhibitors of NF-kB 
(IkB alfa, beta). 
In the presence of a  wide range of stimuli, the inhibitors are phosphorylated 
by IkB  kinase (IKK) complex and degradated by 26S proteasomes 
(Baldwin et al., 2001). Upon activation, NF-kB dimers enter the nucleus, 
where they modulate transcription of many genes encoding cytokines, 
growth factors, cell adhesion molecules, and antiapoptotic proteins (Yang et 
al., 2007). 
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The IKK complex is composed of three subunits: the catalytic subunits 
IKK-α and IKK-β, and the regulatory subunit IKK-γ (also known as 
NEMO). NEMO regulates the IKK complex activity through its binding to 
carboxyl-terminal region of IKKα and IKKβ, termed NEMO-binding 
domain (NBD) (May et al., 2002). 
 
 
 
Figure 6: NF-kB pathways. Signalling network leading to NF-kB activation (see text for 
description). 
 
 
 
 
 
 
 
Introduction 
 14 
Recently, a cell-permeable NBD-peptide has been shown to block the 
association of NEMO with the IKK complex, inhibiting NF-kB activation 
and ameliorating inflammatory responses. This peptide contains carboxyl-
terminal region of  IKK complex catalytic subunits fused with Penetratin, a 
Drosophila melanogaster protein that crosses cell membranes and facilitates 
the entry of the peptide in the cytosol. Once inside, the peptide prevents the 
assembly of the catalytic subunit NEMO, thereby destroying the structural 
and functional integrity of the IKK complex (Di Meglio et al., 2005).  
The potential of this peptide as an anti-inflammatory agent has been 
demonstrated in vivo in various animal models. Importantly, the NBD 
peptide does not completely inhibit NF-kB activity, suggesting that selective 
disruption of the interaction of NEMO and IKK will most likely leave 
residual NF-KB activity that might be sufficient to maintain normal cellular 
processes. 
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1.5 Scientific hypothesis and aim of the work 
   Recently, numerous  studies have demonstrated that  NF-kB  is  
connected with multiple aspects of oncogenesis. In this perspective, 
inhibition of NF-kB is expected to be an ideal therapeutic target in those 
tumours where NF-kB appears to play a unique survival role. In vitro 
experiments  have shown that NF-kB activity is constitutively elevated in 
human melanoma cultures compared to normal melanocytes. 
 The identification of the NEMO-binding domain (NBD) peptide, able to 
block the activation of the IKK complex has provided the possibility to 
selectively modulate the activation of NF-kB transcriptional nuclear factor 
by targeting the NBD-NEMO interaction. 
In this, aim of present research was to verify whether NBD-peptide is able 
to induce programmed cell death in A375 melanoma cells. For this purpose, 
in the first part of the research, we studied cell proliferation at different 
NBD-peptide concentration and NF-kB activity. Later, the apoptosis 
induction was analysed by flow citometry and expression of PARP-1,  that 
is a known marker of this process. 
 In the second part of this work, the poly-ADP-ribosylating system has been 
characterized both in melanocytes and untreated and treated A375 cells. In 
this  reaction products of PARP1 have been isolated from the treated and 
untreated  cells and used as substrate to determine PARG activity. 
Therefore, further seven melanoma cell lines with different mutations were 
examined to verify and/or confirm  the apoptosis induction following NBD-
peptide treatment. 
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MATERIALS AND METHODS  
 
2.1 Cell lines 
Melanocytes are melanin-producing cells located in the bottom layer  
(the stratum basale) of the skin's epidermis. They have an elongated form, a 
large nucleus  and  grow in clusters (Figure 7).   
       
 
 
Figure 7: Melanocyte cells. 
 
The A375 melanoma cells are highly invasive and spontaneously metastatic. 
Morphologically they have undifferentiated shape aspect (form). They have 
a lengthened or polygonal form depending on whether they are plated or in 
suspension (Figure 8A). Moreover, these cells grow through cell-cell 
interaction and in multilayer, so they shape polyhedric and form oval colony 
(Figure 8B). The A375 are changed in BRAF (Serine/threonine protein 
kinase) and therefore the MAPK pathway is constitutively activated.  
                                               A                                        B 
          
 
Figure 8: A375 melanoma cells (A) and (B).     
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2.2 Cell growth and treatment with NBD- peptide 
A375 melanoma cell line and normal human epidermal melanocytes 
 (NHEM) were purchased from Promo Cell (Heidelberg, D-69126, 
Germany). Melanocytes were grown in medium 2 (Promo Cell). A375 in 
complete Dulbecco’s modified Eagle’s medium (DMEM). The media were  
supplemented with 10% FBS, 2mM L-glutamine, additioned with 
antibiotics (100U/ml penicillin, 100 mg/ml streptomycin) and cells 
maintained in humidified atmosphere with 5% CO2 at 37°C. Cell count was 
performed at 0, 24, 48, 72 and 96 hours (Figure 9). 
 
 
Figure 9: Growth curve of A375 cell line. 
The curve  was obtained by counting cells at 0, 24, 48, 72 and 96 hours. These cells show a 
short replication cycle, in which growth is influenced by density of plating. 
 
To investigate whether treatment with NBD-peptide would lead to cell 
death, cell survival was measured by trypan blue dye esclusion on A375 cell 
line; NHEM was used as control. The cells were plated at the concentration 
of  1 x 10
5
 cells/well and were cultured in 2 mL DMEM complete medium 
with NBD-peptide from Genosphere Biotech (Paris, France) at 6.25, 12.5, 
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25, 50, 100M. NBD-peptide was dissolved in DMSO and stock solution 
was stored at -20°C. After incubation for 24 h, cells were collected and an 
aliquot of cell suspension was mixed with equal volume of trypan blue 
0.4%. Viability was determined at the designed intervals by vital-dye 
exclusion assay. The same experiment was carried out at 50 and 100M 
peptide for 3 hours. 
 
2.3 Electrophoretic mobility shift assay (EMSA) 
The cells treated with NBD-peptide (50M), were prepared after lysis 
in extraction buffer (50mM Tris [tris(hydroxymethyl)aminomethane]-HCI, 
pH 7.4, 150mM NaCI, 0.1%Triton X-l00, 5mM EDTA 
[ethylenediaminetetraacetic acid], 1mM Na3V04, and 1mM PMSF 
[phenylmethylsulfonyl fluoride] and protease inhibitors. Double-stranded 
containing the NF-kB (5'-CAACGGCAGGGGAATCTCCCTCTCCT-3T') 
recognition sequence were endlabelled with [
32
P] --ATP. 
Aliquots of whole-A375 cell extracts (12 g protein/sample), treated  for 
different time with NBD-peptide were incubated with [
32
P] -labelled kB-
DNA probe in binding buffer for 30 min (Piva et al., 2005). DNA-protein 
complexes were analyzed by non-denaturing 4% polyacrylamide gel 
electrophoresis in 1x TBE buffer at 150 V for 2 hours at 4°C. The gel was 
dried and autoradiographed using an intensifying screen at -80°C for 20 
hours.  
NF-kB-DNA complex formation was quantitatively determined by 
densitometric analysis performed with a GS-700 imaging densitometer 
(Bio-Rad, Italy) and a data computer program (Molecular Analyst; IBM). 
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2.4 Kinase assay 
 
Cell lysates were immunoprecipitated with anti-IKKa antibodies (Cell 
Signaling Technology) in the presence of 20µL protein-A-Sepharose 
(Sigma) at 4°C for 16 hours. After extensive washing, endogenous IKK 
activity was determined using glutathione-Stransferase (GST)-IKBα as 
substrate (Piva et al., 2005). 
 
2.5 Flow cytometry  
 
To evaluate apoptosis after NBD treatment, cells were treated for 3 
hours with 6.25, 12.5, 25, 50M of NBD peptide. Cells were detached by 
Trypsin/EDTA and apoptosis was detected by measuring the active form of 
caspase-3 by FACS Vantage Cell Sorter cytometer (BD Biosciences, San 
Diego,CA) using the PE-conjugated anti-human-active caspase-3 
monoclonal antibody (mAb) (BD Biosciences, San Diego, CA) and 
following the manufacturer’s instructions. The Data obtained were analyzed 
by Cell Quest Software. Mononuclear cells were washed, fixed, and 
permeabilized by the Cytofix/Cytoperm™ Kit (BD Biosciences, San 
Diego,CA). Briefly, cells were pelleted for 20 min at room temperature 
(RT), and washed with Perm/Wash™ Buffer C. Cells were then stained with 
anti-active caspase-3 mAb using 10 µl / 1x 105 cells for 60 min at RT in the 
dark, washed with Perm/Wash™ Buffer, resuspended in PBS and analyzed 
by flow cytometry. 
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2.6 Cell lysis and isolation of cell nuclei 
 
Nuclear fractions from melanocytes (5 x 10
5
 cells), melanoma control 
cells (5 x 10
5
 cells), and melanoma cells (5 x 10
5
 cells),   treated with NBD-
peptide were isolated by Quiagen kit. Whole fractions were used for the 
following biochemical analyses. 
 
2.7 Polyacrylamide Gel Electrophoresis in Sodium Dodecyl Sulphate, and 
Western Blotting  
 
Nuclear fractions (20g of proteins) from melanocytes, treated and  
untreated A375 were analyzed on 12%  polyacrylamide gels in  the presence 
of 0.1% SDS according to (Nicholas et al., 1982). Gels were stained in 
0.1% Coomassie G in 10% acetic acid 30% methanol. For immunoblotting 
electrophoresed (20g) proteins were transferred onto polyvinylidene 
fluoride (PVDF) membrane (Biorad) at 200 V for 1.5 h at 4°C in the same 
buffer used for  electophoretic run. 
For immunoblot experiments procedures and buffers were according to 
(Faraone Mennella et al., 2005). PVDF sheets were treated for 1.5 h with 
blocking solution (50mM Tris-HCl buffer, pH 8.0; 150mM NaCl; 0.5% 
(v/v), Tween 20 and 3% gelatine). Incubation with commercial  anti- PARP 
1/2 (Santa Cruz, rabbit anti-human PARP, H-250,1:2000, v/v), was 
performed for 2 h at room temperature  in the same solution supplemented 
with 0.3% gelatine. 
The filters were washed several times with TBS-Tween and antibody 
binding was detected by Anti-rabbit  IgG (H+L) horseradish peroxidase 
(1:2000;v/v). Their action was revealed by using a kit for 
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chemiluminescence (Super signal West Dura, Extended Substrate, Pierce) 
and reading by  a Quantitaty One program in a Chemidoc apparatus (Bio-
Rad).  
 
 
  2.8 PARP activity  
 
The ADP-ribosylating activity of the PARP enzyme in whole nuclear  
fractions (20μg proteins) from melanocytes, untreated and treated 
melanoma cells was routinely assayed for 10 minutes at 25°C in the 
presence of 0.51mM [
32
P]NAD
+
 (GE Healthcare Europe GmbH, 
Biosciences) (10, 000 cpm/nmole) (Faraone Mennella et al., 2003). The 
final specific radioactivity (10,000 cpm/nmole) and concentration 
(0.51mM) were reached by mixing labelled and unlabelled 0.51mM NAD
+
. 
The reaction mixture was composed of 500mM Tris-HCl buffer, pH 8.0; 
50mM MgCl2 and 10mM DTT (final volume 50μl).The reaction was 
stopped with ice-cold 30% trichloroacetic acid (TCA) and the radioactivity 
present in the acid insoluble material, collected on HAWP filter (0.45μm, 
Millipore), determined on a Beckman LS 1701 liquid scintillation 
spectrometer.One PARP milliunit (mU) is defined as the amount of enzyme 
required to converte 1nmol of NAD
+
/min. under standard conditions. 
 
 
2.9 Covalent ADPR  Protein Acceptors 
 
Nuclear fractions (20g proteins) from melanocytes and untreated 
 and treated (50M peptide for 6h) cells were incubated under standard 
conditions with [
32
P]NAD
+ 
(50,000 cpm/nmole). The reaction was 
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stopped by transferring the mixture on dry ice and liophylizing. The dried 
samples were suspended in electophoretic buffer and loaded on 
polyacrylamide (12%) gel. Images of stained gels and autoradiographic 
patterns of labeled proteins were acquired by a Phosphor imager (mod. 
Fx, Biorad). Densitometric analysis of radioactive ADPR protein 
acceptors was performed using Personal molecular image FX and  
Quantity One Programm (BIO-RAD). 
 
2.10 Western blotting with anti-PARG antibodies  
 
Nuclear extracts (20g proteins) from melanocytes, untreated and  
treated A375 melanoma cells (NBD peptide 50M for 6h) were separated 
by SDS-PAGE. Western Blot analysis was performed as previously 
described, using anti-PARG MaxPab mouse  polyclonal (B01) (Abova, 
1:200; v/v) and anti-mouse IgG (H+L) horseradish peroxidase (Pierce, 
1:1000; v/v),  as primary and secondary antibodies respectively. 
 
 
 2.11 PARG purification  
 
Poly(ADP-ribose) glycohydrolase was purified from untreated and 
treated A375 by electroeluition of band corresponding to molecular weight 
of  PARG enzyme from SDS–PAGE 12%.  
After electrophoresis of nuclear fractions (200g proteins), the gel was 
stained for 15 min with Coomassie Blue G. As soon as the protein of 
interest became visible, the band was cut out with a razor blade. The gel 
piece was washed and placed into a dialysis tube (14, 000 c.o.), containing 
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1mL of electroelution buffer (0.01M Tris-acetate pH 8.6). The tube was 
placed in the electroelution apparatus containing 0.01M Tris-acetate  pH 8.6 
in the central  lodging and 0.04M Tris-acetate in the lateral lodging. The 
electroelution was carried out at 8mA overnight. The concentration of 
electroeluted protein was determined by the Bradford  method (Bradford et 
al., 1976). The electroeluted protein  was analyzed by SDS-PAGE and 
identified by Western Blotting with anti-PARG antibodies as already 
described. 
 
2.12 PolyADP-ribosylating proteins determination after PARG assay 
 
Two nuclear fractions (each of 100g) from untreated and treated  
A375 cells were incubated with 0.51mM [
32
P] NAD
+
 (10,000 cpm/nmole) in 
a reaction mixture composed of 500mM Tris-HCl buffer, pH 8.0; 50mM 
MgCl2 and 10mM DTT (final volume 50l),  according to PARP standard 
assay described in  (De Lucia et al., 1996).  
The reaction was stopped with ice and the ADP-ribosylating proteins were 
precipitated by trichloroacetic acid (TCA) (30% final) and washed with 
ethanol. One of two fractions from each samples, containing the ADP-
ribosylating proteins were re-incubated in a 50μl reaction mixture 
containing 100mM Tris-HCl, pH 8.0, 10mM dithiothreitol and  purified 
PARG (6g/ml) (PARG assay). The other  fractions  were incubated in the 
same reaction mixtures without PARG enzyme (control). The reactions were 
stopped  by addition of  ice-cold TCA (30% final) and the residual 
radioactivity associated to proteins was collected on HAWP filter (0.45m, 
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Millipore) and measured by a Beckman LS 1701 liquid scintillation 
spectrometer. 
 
2.13 Synthesis and purification of protein-free poly(ADP-ribose) 
 
Protein-free [
32
P] Poly(ADP-ribose) from nuclear fractions untreated  
 and treated (50M peptide) cells were synthesized in a 500μl reaction 
mixture containing 500mM Tris-HCl buffer, pH 8.0; 50mM MgCl2, 10mM 
DTT and  0.51mM [
32
P] NAD  ( 100,000 cpm /nmol). The reaction mixture 
was incubated for 10 min at 25°C and proteins precipitated by 20% 
trichloroacetic acid. Subsequently, this pellet was incubated with Tris  
NaOH 10mM pH 12, containing 1mM EDTA for 2 h at 60°C  to release 
polymers from protein. Finally, protein-free [
32
P]poly(ADP-ribose) was 
extracted three times with isoamilic alcohol/chloroform (1:49; v/v) and 
separated by 20% polyacrylamide gel electrophoresis, according to 
(Panzeter et al., 1993). Finally, dried gel was exposed to autoradiography 
film over night and revealed by Phosphor imager ( mod. Fx, BIO-RAD). 
 
 
2.14. Electrophoretic identification of PARG reaction products  
 
[
32
P]poly(ADP-ribose) (2,000 cpm, 70 nCi/nmol ADP-ribose) and   
purified PARG  (6g/ml) [32P]poly(ADP-ribose) were incubated for 5, 10 
and 15 minutes  at 37°C in a 50 μl reaction mixture containing 100mM Tris-
HCl, pH 8.0, 10mM dithiothreitol (standard PARG assay).  The reaction 
was stopped by addition of SDS 01% final concentration and transferring  
the mixtures to 60°C for 10 min. The digested products of [
32
P]poly(ADP-
ribose) were freed of proteins by  incubation with Proteinase K (SIGMA, 
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0.2 mg/ml) for 1 h at 37°C and separated by 20% polyacrylamide gel 
electrophoresis (Panzeter et al., 1993). 
The dried gel was exposed to autoradiography film over night and revealed 
by Phosphor imager  (mod. Fx, BIO-RAD). 
 
2.15 Different melanoma cell lines 
 
SK-MEL2, 397, SK-MEL5 , M14, LOX , SK-MEL28, UACC257 
 were from NCI-Frederick Cancer Center DCTD Tumor/Cell Repository 
were cultured in RPMI1640 (Gibco BRL Life Technologies, Rockville, 
MD, USA) supplemented with 10% FBS (Htclone, Logan, UT, USA ), 
2mM L-glutamine, additioned with antibiotics (100U/ml penicillin, 100 
mg/ml streptomycin) and maintained in humidified atmosphere with 5% 
CO2 at 37°C.  
The cells treated with NBD-peptide at the concentration of 50M for 6 
hours, were analyzed by flow cytometry and western blotting with anti-
PARP antibodies as previously described for A375 cells. PARP activity of 
whole cells was also determined. 
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RESULTS 
 
3.1 Treatment of A375 cells by different concentrations of NBD-peptide 
 
A375 melanoma cells were treated with NBD-peptide at concentrations 
of 6µM, 12µM, 25µM, 50µM and 100µM for 24h (Figure 10). This 
treatment induces a dose-dependent inhibition of melanoma proliferation. 
The highest inhibition of proliferation (60%) occurs when A375 cells are 
treated with 50µM peptide. A higher concentration of peptide (100µM) does 
not produce further inhibition after 24 hours of incubation (Figure 10). 
Comparable results were obtained in the presence of 50µM peptide for 3h 
(data not shown). 
 
 
  
Figure 10: Inhibition of A375 cell growth by NBD peptide treatment for 24 hours. 
Different concentrations of NBD-peptide were tested, with maximal inhibition at 50µM of 
peptide. As negative control melanocytes growth was tested also in presence of 50 µM 
NBD-peptide (data not shown).  
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3.2  Modulation by NBD-peptide of NF-kB activation 
 
  The experiment was focused to test both the levels of NF-kB activity 
by EMSA assay, and to study the role of IKK complex and its regulation by 
NBD-peptide. First, cells were treated  with 50µM NBD-peptide to get 
maximal growth inhibition for different time. Samples were analyzed by 
EMSA assay, in order to investigate whether the peptide modulates NF-kB 
activity. EMSA assay was carried out using the NF-kB (5'-
CAACGGCAGGGGAATCTCCCTCTCCT-3T') recognition sequence, end-
labelled with [
32
P]--ATP (as described in Materials and Methods, 2.3). The 
autoradiography of electrophoretic mobility shift assay showed a reduction 
of NF-kB activity, in a time-dependent manner, as confirmed by 
densitometric analysis  (Figure 11A and B). 
 
 
Figure 11: Modulation of NF-kB activity in A375 cells treated with 50 µM of NBD-
peptide for 3h, 6h, and 24h.  
(A) Non-denaturating 4% polyacrylamide gel electrophoresis; (B) Densitometric Analysis. 
1= untreated A375 cells; 2= A375 cells treated with (50µM) NBD- peptide for 3h; 3=  
A375 cells treated with (50µM) NBD-peptide for 6h; 4= A375 cells treated with (50µM) 
NBD-peptide for 24h.  
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On the other hand to determine whether inhibition of constitutive NF-kB 
activity could be the result of down regulation of the upstream IKK activity 
by the NBD-peptide, we performed an IKK-activity assay on A375 human 
melanoma cells.  
The high activity of IKK in A375 human melanoma cells, measured as 
incorporation of radiolabelled [
32
P] into GST-IKBα, was reduced by the 
NBD-peptide in a time-dependent fashion. As indicated in Figure 12, the 
IKK activities were reduced by 46%, 51%, and 66% in response to the 
NBD-peptide treatment of  50μM for 3, 6 and 24 hours, respectively. 
 
     
                                          
   
Figure 12: Analysis of reaction products from IKK activity on GST-IKBα by SDS-
polyacrylamide gel (10%).  
(A) Autoradiography of gel; (B) Densitometric Analysis; 1= untreated A375 cells; 2= A375 
cells treated with (50µM) NBD-peptide for 3h; 3=  A375 cells treated with (50µM) NBD-
peptide for 6h; 4= A375 cells treated with (50µM) NBD- peptide for 24h.  
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3.3 Effect of NBD-peptide on apoptosis induction  
Caspase3 activation and levels of apoptotic PARP-1 fragment (89kDa) 
are routinely used as marker of apoptosis. Therefore, in order to characterize 
the mechanism underlying the results described in the previous section, 
A375 melanoma cells were exposed to the NBD-peptide at different 
concentrations (6.25, 12.5, 25, and 50µM) for 3h and then were analyzed by 
flow cytometry after incubation with PE-conjugated anti-human-active 
caspase-3 monoclonal antibodies (mAb). Results clearly showed a dose-
dependent activation (20.3%, 25.0%, 30.9% and 40.2% respectively) 
(Figure 13). Again the maximal value (40,2%) corresponded to cells treated 
with 50µM of NBD-peptide.  
 
 
 
    
Figure 13: Cytometry  analysis  of treated A375 NBD-peptide for 3h. 
A= 6.25µM NBD-peptide; B= 12.5µM NBD-peptide; C= 25µM NBD-peptide; D= 50µM 
NBD-peptide. A375 cells were analyzed with the monoclonal antibodies (mAb) PE-
conjugated anti-human-active-caspase3.             
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During apoptosis,  PARP-1, the best marker of this process, is cleaved by 
caspase3 in two fragments of 89kDa and 24kDa, respectively. For this 
reason, to evidence whether NBD-peptide treatment induces apoptotic 
process in A375 cells, electrophoretic analysis (Figure 14A) following by 
western blotting with commercial anti-PARP antibodies (Figure 14B) was 
carried out on nuclear fractions from melanocytes (control), untreated and 
treated A375 cells. They were treated with 50µM NBD-peptide for 3, 5, 6 
hours. 
Immunoblot  showed immunoreactive signals of 113kDa (native enzyme) 
and 89kDa (cleaved form). In contrast to untreated cells, the 113kDa band 
decreases and the 89kDa increases after NBD treatment.  The increase of 
89kDa fragment confirms that most A375 cells undergo apoptosis at levels 
comparable to those of melanocytes. 
 
Figure 14: Analysis of nuclear fractions from melanocytes, untreated and treated 
A375 cells with 50µM of NBD-peptide for 3, 5, 6 hours.  
(A) SDS-polyacrylamide gel (12%) stained in  Coomassie, (B) Immunoblotting with anti-
PARP-1 Abs. Nuclear fractions from: 1=1’ melanocytes; 2=2’ A375 cells; 3=3’ A375 
treated with 50µM NBD-peptide for 3h; 4=4’ A375 treated with 50µM NBD-peptide for 
5h; 5=5’ A375 treated with 50µM NBD-peptide for 6h. 
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3.4 Effect of NBD-peptide on PARP activity.   
 
   To confirm the PARP-1 catalytic fragment (89kDa) is inactive, the  
enzyme activity was measured in nuclear fractions of melanocytes, 
melanoma cells  both before and after treatment with NBD-peptide at 25µM 
(Figure 15A), 50µM (Figure 15B) and 100µM (Figure 15C) for 3, 5 and 6 
hours. Reaction mixtures prepared as  described in Materials and Methods  
(section 2.8) cointained an isotopic dilution of  PARP-1 substrate  [
32
P] 
NAD
+
 and the same amount of proteins (20µg). The levels of PARP-1 
activity  in melanocytes are significantly lower than those measured in A375 
melanoma cells (Figure 15). The treatment with NBD-peptide (25 and 
50M) reduces enzyme activity in a time- and a dose-dependent manner. 
The maximum decrease of enzyme activity (84%) occurs after incubation of 
tumoral cells with 50 M peptide for 6 hours (Figure 15B). Further activity 
reduction is not evident after treatment  at higher concentrations of peptide 
(100M) (Figure 15C). 
As PARP-1 is the best consumer of  intracellular  energy, its partial 
inactivation ensures both induction and maintenance of apoptotic state. 
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Figure 15:  PARP-1 activity in nuclear fractions from melanocytes, untreated  and 
treated A375 cells with 25µM, 50µM and 100µM NBD-peptide.  
c= melanocytes; A375= untreated cells; 3h= A375 cells treated for 3h; 5h= A375 cells 
treated for 5h;  6h=  A375 cells treated for 6h. 
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The same nuclear suspensions of melanocytes, untreated A375 cells and 
treated cells with 50M of NBD-peptide for 6h were incubated with [32P] 
NAD
+ 
in standard assay conditions and electrophoresed, to evidence 
covalent protein acceptors of ADPR. The autoradiographic analysis revealed 
the presence of a single signal to the top of gel (Figure 16A). The 
densitometric analysis  of autoradiographic bands showed that the entity of 
the modification is bigger in untreated than in treated cells and in 
melanocytes (Figure 16C). Although, this experiment didn’t allow to 
highlight the possible ADPR acceptors, however it confirmed that the poly-
ADPR produced in treated cells decreases following treatment with NBD-
peptide. In melanocytes, where the lowest PARP-1 activity was measured, 
we observed the lowest production of polymer. 
 
 
Figure 16: Analysis of protein acceptors. 
 (A) SDS-polyacrylamide gel (12%) stained in  Coomassie, (B) Autoradiographic analysis 
of protein acceptors and (C) densitometric analysis of B. Nuclear fractions from: 1=1’ 
A375 cells; 2=2’ A375 cells treated with 50µM NBD-peptide for 6h; 3=3’ melanocytes. 
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 3.5 PolyADP-ribose turnover 
The effect of cells treatment with NBD-peptide on PAR turnover was  
studied. PARG is responsible of the conversion of PAR into ADP-ribose 
units; therefore its behaviour was analyzed and compared to that of the 
enzyme of PAR synthesis, PARP-1. 
PARG expression in  nuclear fractions from untreated and treated A375 
cells  was evidenced by electophoretic analysis (Figure 17A) followed by 
Western Blotting with anti-PARG antibodies (Figure 17B). In both samples, 
a single immunoreactive band corresponding to the PARG isoform with a 
molecular weight of about 70-75kDa  was observed.  
 
Figure 17: Analysis of PARG enzyme expression from A375 melanoma cells. 
Treatment was with 50µM NBD-peptide for 6h. (A) SDS-polyacrylamide gel (12%) stained 
in  Coomassie, (B) Immunoblotting with anti-PARG Abs. Nuclear fractions from: 1=1’ 
untreated A375 cells; 2=2’ treated cells. 3=3’ purified PARG from nuclear fraction of A375 
cells; 4= 4’ purified PARG from nuclear fraction of treated A375 cells. 
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Purified PARG fractions from both untreated and treated A375 cells were 
used to determine enzyme activity at different incubation times (Figure 18). 
The poly-ADPR produced by PARP assay and protein-bound (acid- 
insoluble fractions), was used as substrate. The highest levels of [
32
P]-PAR 
labelled ADP-ribosylating proteins (taken as 100%) were measured in 
melanoma A375, as compared with treated cells (reduced to 20-25%). The 
values at zero time were obtained by measuring the [
32
P]-PAR incorporation 
into proteins before addition of the corresponding electroeluted PARG 
fractions. The time course of the reaction clearly showed that in untreated 
cells, 5 minutes were enough for PARG to remove more than 90% [
32
P]-
PAR, whereas the already low levels of [
32
P]-PAR (20-25%) from treated 
cells did not change significantly over the whole incubation time with NBD-
treated cell purified PARG (Figure 18). 
 
 
 
Figure 18: Time course of PARG assay using as substrate  PAR-proteins adducts. 
100% radioactivity corresponded to 8,000 cpm acid-insoluble material. 
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Morever, protein-free [
32
P]poly(ADP-ribose) isolated from untreated and 
treated A375 cells were analysed by 20% polyacrylamide gel (Figure 19). 
The results showed different PARP reaction products: a  long and complex  
polymer purified from untreated A375 cells (Figure 19, lane1) and a linear 
chain of 20-25 ADPR units from treated cells (Figure 19, lane4). Incubation 
of PARP products from untreated cells with its corresponding purified 
PARG fractions, gave a complete degradation to ADPR of  the polymer 
(Figure 19, lane2), whereas a scarce hydrolysis occurred when treated-cell 
polyADPR was incubated with its purified PARG (Figure 19, lane5). 
 
Figure 19: Separation of protein-free [
32
P]-labelled-polyADPR from untreated and 
treated A375 cells and their digestion products. Treatment was with 50µM NBD-peptide 
for 6h. XC, xylene cyanol blue dye; BrΦ, bromophenol blue dye; 1= PAR from A375 cells; 
2= PAR from A375 cells after PARG assay; 3= [
32
P] NAD
+
; 4= PAR from A375 treated 
cells; 5= PAR from A375 treated cells after PARG assay. 
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Our experiments showed that despite PARG activity is lower in treated  
A375 cells than in untreated ones,  a single PARG isoform was found. This 
result suggests that the altered PARG activity could depend on the ongoing 
of the  apoptotic process.  
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3.6 NBD-treatment of different melanoma cell lines results in apoptosis  
 
On the basis of previous results, the effects of NBD- peptide treatment 
 (50µM for 6h) on SK-MEL2, 397, SK-MEL5, M14, LOX, SK-MEL28, 
UACC257 cells were studied by using biochemical analyses described in 
the previous sections. 
FACS analysis clearly showed that also in these melanoma cells NBD-
peptide is able to activate  the caspase3 to induce the apoptotic process 
(Figure 20). 
 
 
   
 
Figure 20: Cytometry analysis. Cell lines were analyzed using the monoclonal antibody 
(mAb) PE-conjugated anti-human-active-caspase3. 
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We also tested the production of cleaved fragment of PARP-1(89kDa) due 
to caspase3 activity. Immunoblotting of samples showed the lack of the 
113kDa band corresponding to native PARP-1 and the simultaneously 
appearance of its apoptotic fragment (89 kDa) produced by caspase-3 
activity in M14, 397, UACC257, after treatment with NBD-peptide (Figure 
21B). 
 
  
Figure 21: Analysis of nuclear fractions from melanocytes, untreated and treated 
melanoma cells.  
Treatment was  with 50µM NBD-peptide for 6 hours. (A) SDS-polyacrylamide gel (12%) 
stained in  Coomassie, (B) Immunoblotting with anti-PARP-1 Abs. 1= M14; 2= treated 
M14; 3= 397; 4= treated 397; 5= UACC257; 6= treated UACC257; 7= Melanocytes.  
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Untreated SK-MEL5, SK-MEL2, LOX and SK-MEL28 cell lines showed 
the 113kDa band of  PARP-1 and an additional band of 60kDa, that 
probably corresponds to PARP-2 protein (Figure 22, lanes 1’,3’,5’,7’). 
 After PARP-1 apoptotic fragment (89 kDa), with no change of the 60 kDa 
signal (Figure 22B, lanes 2’,4’,6’,8’). 
 
 
 
                            
Figure 22: Analysis of nuclear fractions from melanocytes, untreated and treated 
melanoma cells. 
Treatment was  with 50µM NBD-peptide for 6 hours. (A) SDS-polyacrylamide gel (12%) 
stained in  Coomassie, (B) Immunoblotting with anti-PARP-1 Abs. Cell lines 1= SK-
MEL5; 2= SK-MEL5; 3= SK-MEL2; 4= treated SK-MEL2; 5= LOX, 6= treated LOX; 7= 
SK-MEL28; 8= treated  SK-MEL28. 
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PARP activity was also measured in all the cells described before and 
treated with NBD-peptide at 50µM for 6h. The treatment produces an 
evident decrease of poly(ADPR-ribosyl)ation in all the examined cells 
(Figure 23). 
 
 
 
 
Figura 23: PARP activity before and after treatment with 50µM NBD-peptide  for 6h. 
 1=M14; 2= treated M14; 3= 397; 4= treated 397; 5= UACC257; 6= treated UACC257; 7= 
SK-MEL5; 8= treated SK-MEL5; 9= SK-MEL2; 10= treated SK-MEL2; 11= LOX; 12= 
treated LOX; 13= SK-MEL28; 14= treated SK-MEL28. 
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DISCUSSION 
 
The polyADP-ribosylation reaction results in a unique post-translation 
modification involved in various cellular processes and conditions, 
including DNA repair, transcriptional control, genomic  stability, cell death 
and cancer. It has been also reported that this process  plays a main role in 
both anti- and pro-inflammatory events (Hottiger et al., 2010., Kiliańska et 
al., 2010). As the inflammation is a critical component in carcinogenesis, 
recent studies were carried out to define  new anti-inflammatory therapies 
for a complementary approach in treating a variety of tumor types. These 
observations highlighted NF-kappa B pathway as an attractive way for drug 
discovery and development (Lin et al., 2010). The recent identification of 
the NEMO-binding domain (NBD) peptide with anti-inflammatory activity, 
able to block the activation of the IkB kinase (IKK) complex, allowed to 
hypothesize the apoptosis induction in those tumours, in which NF-kB is 
constitutively activated (Di Meglio et al., 2005).   
According to this hypothesis, we treated A375 melanoma cells with NBD 
peptide. Treatments resulted in a concentration-dependent inhibition of cell 
proliferation (Figure10). This effect has been associated with the direct 
inhibition of NF-kB DNA-binding activity (Figure 11), IKK activity (Figure 
12), and with  caspase3 activation (Figure 13), confirmed  by the partial  
PARP-1 cleavage (Figure 14) and by the decrease of its activity (Figure 15). 
Very interestingly, a net immunopositive signal, corresponding to PARP-1  
catalytic fragment and a very low polyADP-ribosylating activity have been 
evidenced in melanocytes too (Figure 14, 15). 
These results demonstrate that in melanocyte cells a physiological apoptosis 
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is active, while, in A375 treated cells, the NBD peptide is able to induce this 
process. 
In the second part of this research,  the complete ADP-ribosylating system 
in NBD-peptide untreated/treated melanoma cells has been described, in 
order to evidence whether this new potential drug might influence the 
synthesis and degradation of PAR. Its intracellular levels are important in 
both death and life of cells  (Heeres et al., 2007).  
In  all examined A375 cells  and in melanocytes, a single signal was at top 
of gel,  likely  PARP-1 itself. (Figure 16). 
The different automodification entity (Figure 16), the length and the  
complexity of polyADPR (Figure 19) seem to influence PAR turnover, 
guaranteed by a nuclear PARG immunoreactive band of 75kDa (Figure 
17).We don’t know whether this is a fragment of cytoplasmic PARG 
(111kDa) translocated to the nucleus (Affar et al., 2001)  or a nuclear 
isoform of this enzyme (Tanuma et al.,1990). However, our results clearly 
shown that in untreated cells,  the long and branched ADPR polymers 
(Figure 19) are almost completely digested by PARG enzyme (Figure 19). 
On the other hand, in  treated cells, the short oligomers (about 25-30 units) 
(Figure 19) are only partially digested (Figure 19). 
 On the basis of these evidences, we hypothesize that the complete ADP-
ribosylating  system, including synthesis and degradation of PAR by  
PARP-1 and  PARG respectively, could be involved in the mainteinance of 
apoptotic process induced by NBD-peptide treatment. 
 In fact, as high intracellular PAR concentrations are responsible for cell 
death by necrosis (Ying et al., 2001), in treated cells, the low levels of poly-
ADP-ribosylated proteins combined with low PARG activity (Figure 18) 
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might allow the cells to maintain an apoptotic state. 
At last, the evidence that in all examined cells, the NBD-peptide induces 
apoptosis, as it is  confirmed by PARP-1, allowed to hypothesize that this  
drug  could represent a new and effective therapy tool  for melanoma.  
Until now, many drugs able to inhibit NF-kB activity have been tested (Nasr 
et al., 2005., Richardson et al., 2004), but one of the most relevant problems 
of a cancer therapy based on inhibition of NF-kB activity is represented by 
the difficulty to find compounds which block the oncogenic activity of NF-
kB without interfering with its roles in immunity, inflammation and cellular 
homeostasis. An important aspect of our research is that NBD-peptide does 
not completely inhibit the transcriptional nuclear factor activity, but 
produces only its selective modulation. In this way, its physiological 
functions are not affected. 
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